2+ day, 21+ hour ago   (207+ words) That’s why the Novel CNS Biomarkers Summit Europe comes at a timely moment, bringing together Europe's leading biomarker, translational medicine, neuroscience and clinical development experts to tackle one of the industry's biggest challenges: improving clinical trial success in CNS drug…...

2+ day, 21+ hour ago   (529+ words) Some pharmacists in England can now prescribe medicines for acne, migraines, scabies, ear infections, and rhinitis in a major expansion of the Pharmacy First scheme first introduced in 2024. The five new categories, first announced by the UK government in May…...

2+ day, 21+ hour ago   (545+ words) There's been a lot of talk about forging closer ties between Europe and Canada in response to the US' aggressive disruption of international trade. Now, two senior figures in Canada's life sciences sector have said they see scope for greater…...

2+ day, 22+ hour ago   (417+ words) Patients with a rare autoimmune disease known as MOGAD could be just a few months away from having the first approved treatment. The FDA has just started a priority review of Roche's anti-IL-6 inhibitor Enspryng (satralizumab) for MOGAD – myelin oligodendrocyte…...

3+ day, 29+ min ago   (585+ words) Gilead's twice-yearly injectable for pre-exposure prophylaxis (PrEP) of HIV, lenacapavir, will not be routinely funded by the NHS, according to initial draft guidance from reimbursement authority NICE. NICE said that the cost-effectiveness figures for lenacapavir are above the range that…...

3+ day ago   (561+ words) World Malaria Day is an annual global health observance originally established by WHO Member States in 2007 to raise awareness about malaria and mobilise action to prevent, control, and ultimately eliminate the disease. To find out more, pharmaphorum spoke with Victoria…...

2+ day, 23+ hour ago   (562+ words) Bayer has won FDA approval for oral HER2 inhibitor Hyrnuo as a first-line treatment for advanced HER2-mutant non-small cell lung cancer (NSCLC), just a year after it was cleared as a second-line option. Hyrnuo (sevabertinib) has been cleared for earlier use…...

3+ day, 1+ hour ago   (403+ words) Pharmaceutical firms are making an expensive mistake. They develop a drug, see it through clinical trials, and only then pause to ask whether it will secure reimbursement. But by then, capital has already been committed, and the drug has already…...

3+ day, 21+ hour ago   (548+ words) BMS CAR-T scientists at work. Bristol Myers Squibb's GPRC5D-directed CAR-T therapy, arlocabtagene autoleucel (arlo-cel), has shown activity in a phase 2 trial that could underpin future filings for blood cancer multiple myeloma. The pivotal QUINTESSENTIAL trial of the potentially first-in-class CAR-T…...